These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 22113498)

  • 1. c-Met inhibitor synergizes with tumor necrosis factor-related apoptosis-induced ligand to induce papillary thyroid carcinoma cell death.
    Bu R; Uddin S; Ahmed M; Hussain AR; Alsobhi S; Amin T; Al-Nuaim A; Al-Dayel F; Abubaker J; Bavi P; Al-Kuraya KS
    Mol Med; 2012 Mar; 18(1):167-77. PubMed ID: 22113498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small molecule c-MET inhibitor PHA665752: effect on cell growth and motility in papillary thyroid carcinoma.
    Chattopadhyay C; El-Naggar AK; Williams MD; Clayman GL
    Head Neck; 2008 Aug; 30(8):991-1000. PubMed ID: 18327775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coexpression of activated c-Met and death receptor 5 predicts better survival in colorectal carcinoma.
    Uddin S; Hussain AR; Ahmed M; Al-Sanea N; Abduljabbar A; Ashari LH; Alhomoud S; Al-Dayel F; Bavi P; Al-Kuraya KS
    Am J Pathol; 2011 Dec; 179(6):3032-44. PubMed ID: 21978492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Downregulation of SKP2 in Papillary Thyroid Cancer Acts Synergistically With TRAIL on Inducing Apoptosis via ROS.
    Pratheeshkumar P; Siraj AK; Divya SP; Parvathareddy SK; Begum R; Melosantos R; Al-Sobhi SS; Al-Dawish M; Al-Dayel F; Al-Kuraya KS
    J Clin Endocrinol Metab; 2018 Apr; 103(4):1530-1544. PubMed ID: 29300929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HGF/c-Met pathway has a prominent role in mediating antiapoptotic signals through AKT in epithelial ovarian carcinoma.
    Bu R; Uddin S; Bavi P; Hussain AR; Al-Dayel F; Ghourab S; Ahmed M; Al-Kuraya KS
    Lab Invest; 2011 Jan; 91(1):124-37. PubMed ID: 20661229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fatty acid synthase and AKT pathway signaling in a subset of papillary thyroid cancers.
    Uddin S; Siraj AK; Al-Rasheed M; Ahmed M; Bu R; Myers JN; Al-Nuaim A; Al-Sobhi S; Al-Dayel F; Bavi P; Hussain AR; Al-Kuraya KS
    J Clin Endocrinol Metab; 2008 Oct; 93(10):4088-97. PubMed ID: 18682509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Scatter factor protects tumor cells against apoptosis caused by TRAIL.
    Fan S; Meng Q; Laterra JJ; Rosen EM
    Anticancer Drugs; 2010 Jan; 21(1):10-24. PubMed ID: 19823077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of X-Linked Inhibitor of Apoptosis as a Prognostic Marker and Therapeutic Target in Papillary Thyroid Carcinoma.
    Hussain AR; Bu R; Ahmed M; Jehan Z; Beg S; Al-Sobhi S; Al-Dayel F; Siraj AK; Uddin S; Al-Kuraya KS
    J Clin Endocrinol Metab; 2015 Jul; 100(7):E974-85. PubMed ID: 25974735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Downregulation of Nrf2 by the combination of TRAIL and Valproic acid induces apoptotic cell death of TRAIL-resistant papillary thyroid cancer cells via suppression of Bcl-xL.
    Cha HY; Lee BS; Chang JW; Park JK; Han JH; Kim YS; Shin YS; Byeon HK; Kim CH
    Cancer Lett; 2016 Mar; 372(1):65-74. PubMed ID: 26721202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sunitinib inhibits papillary thyroid carcinoma with RET/PTC rearrangement but not BRAF mutation.
    Jeong WJ; Mo JH; Park MW; Choi IJ; An SY; Jeon EH; Ahn SH
    Cancer Biol Ther; 2011 Sep; 12(5):458-65. PubMed ID: 21725210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma.
    You H; Ding W; Dang H; Jiang Y; Rountree CB
    Hepatology; 2011 Sep; 54(3):879-89. PubMed ID: 21618573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin.
    Ma PC; Schaefer E; Christensen JG; Salgia R
    Clin Cancer Res; 2005 Mar; 11(6):2312-9. PubMed ID: 15788682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. c-Met-mediated reactivation of PI3K/AKT signaling contributes to insensitivity of BRAF(V600E) mutant thyroid cancer to BRAF inhibition.
    Byeon HK; Na HJ; Yang YJ; Kwon HJ; Chang JW; Ban MJ; Kim WS; Shin DY; Lee EJ; Koh YW; Yoon JH; Choi EC
    Mol Carcinog; 2016 Nov; 55(11):1678-1687. PubMed ID: 26456083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts.
    Puri N; Khramtsov A; Ahmed S; Nallasura V; Hetzel JT; Jagadeeswaran R; Karczmar G; Salgia R
    Cancer Res; 2007 Apr; 67(8):3529-34. PubMed ID: 17440059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High prevalence of mTOR complex activity can be targeted using Torin2 in papillary thyroid carcinoma.
    Ahmed M; Hussain AR; Bavi P; Ahmed SO; Al Sobhi SS; Al-Dayel F; Uddin S; Al-Kuraya KS
    Carcinogenesis; 2014 Jul; 35(7):1564-72. PubMed ID: 24583924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination therapy with c-met inhibitor and TRAIL enhances apoptosis in dedifferentiated liposarcoma patient-derived cells.
    Jo EB; Lee YS; Lee H; Park JB; Park H; Choi YL; Hong D; Kim SJ
    BMC Cancer; 2019 May; 19(1):496. PubMed ID: 31126284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FoxM1 and its association with matrix metalloproteinases (MMP) signaling pathway in papillary thyroid carcinoma.
    Ahmed M; Uddin S; Hussain AR; Alyan A; Jehan Z; Al-Dayel F; Al-Nuaim A; Al-Sobhi S; Amin T; Bavi P; Al-Kuraya KS
    J Clin Endocrinol Metab; 2012 Jan; 97(1):E1-E13. PubMed ID: 22049175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting MET by tyrosine kinase inhibitor suppresses growth and invasion of nasopharyngeal carcinoma cell lines.
    Lau PC; Wong EY
    Pathol Oncol Res; 2012 Apr; 18(2):357-63. PubMed ID: 21866424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MEK inhibitor PD0325901 significantly reduces the growth of papillary thyroid carcinoma cells in vitro and in vivo.
    Henderson YC; Chen Y; Frederick MJ; Lai SY; Clayman GL
    Mol Cancer Ther; 2010 Jul; 9(7):1968-76. PubMed ID: 20587665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRAF-activated LncRNA functions as a tumor suppressor in papillary thyroid cancer.
    Liao T; Qu N; Shi RL; Guo K; Ma B; Cao YM; Xiang J; Lu ZW; Zhu YX; Li DS; Ji QH
    Oncotarget; 2017 Jan; 8(1):238-247. PubMed ID: 27462868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.